Roivant Sciences (ROIV) Enterprise Value (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Enterprise Value came in at -$1.1 billion in Q1 2026, up 57.83% YoY from -$673.0 million in Q1 2025, and up 72.23% on a QoQ basis from -$3.8 billion in Q4 2025.
Roivant Sciences (ROIV) Enterprise Value (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Enterprise Value data on file, last reported at -$1.1 billion in Q1 2026.
- Quarterly Enterprise Value rose 57.83% year-over-year to -$1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.1 billion (up 57.83% YoY) and the FY2026 annual result came in at -$1.1 billion, up 57.83% from the prior year.
- Enterprise Value climbed to -$1.1 billion in Q1 2026, from -$3.8 billion in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$42.6 million in Q4 2024 to a low of -$6.4 billion in Q4 2023.
- A 5-year average of -$2.7 billion and a median of -$1.9 billion in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value surged 99.34% — and 2025, when it tumbled 8873.63%.
- Tracing ROIV's Enterprise Value over 5 years: stood at -$1.8 billion in 2022, then plunged by 258.08% to -$6.4 billion in 2023, then surged by 99.34% to -$42.6 million in 2024, then plunged by 8873.63% to -$3.8 billion in 2025, then jumped by 72.23% to -$1.1 billion in 2026.
- The last three Enterprise Value figures came in at -$1.1 billion (Q1 2026), -$3.8 billion (Q4 2025), and -$3.9 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -3.15 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.15 Bn |
| Mar 31, 2026 | -1.06 Bn |
| Dec 31, 2025 | -3.83 Bn |
| Sep 30, 2025 | -3.94 Bn |
| Jun 30, 2025 | -4.03 Bn |
| Mar 31, 2025 | -2.52 Bn |
| Dec 31, 2024 | -42.63 Mn |
| Sep 30, 2024 | -1.89 Bn |
| Jun 30, 2024 | -5.50 Bn |
| Mar 31, 2024 | -6.02 Bn |
| Dec 31, 2023 | -6.45 Bn |
| Sep 30, 2023 | -1.27 Bn |
| Jun 30, 2023 | -1.31 Bn |
| Mar 31, 2023 | -1.23 Bn |
| Dec 31, 2022 | -1.80 Bn |
| Sep 30, 2022 | -1.25 Bn |
| Jun 30, 2022 | -1.57 Bn |
| Mar 31, 2022 | -2.36 Bn |
| Dec 31, 2021 | -2.18 Bn |
| Sep 30, 2021 | -2.91 Bn |